Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study.
Stefano GranieriChristian CotsoglouAlessandro BonomiLisa SalvatoreRoberto FilippiOlga NigroFabio GelsominoIna Valeria ZurloIlaria DepetrisRiccardo GiampieriRossana BerardiCristina MorelliMichele De TursiMichela RobertoElson GjoniAlessandro GerminiNicola De' AngelisRiccardo MemeoAntonio FacciorussoOrnella GarroneDaryl RamaiMichele GhidiniMaria Concetta FargnoliPublished in: Cancers (2022)
In our selected population of left-sided RAS/BRAF wild-type colorectal cancer patients with liver-limited disease, a conversion strategy was confirmed to provide a survival benefit. Patients not deemed surgical candidates at the time of diagnosis and patients judged resectable with perioperative systemic treatment have similar survival outcomes.